The silencing of BTLA or its ligand HVEM promotes cell proliferation via the ERK1/2 pathway, suggesting that tumor cell-intrinsic BTLA/HVEM is a potential tumor suppressor and is likely to have a potential antagonist for immunotherapy. Here, TNFRSF14 is linked to neoplasm.